Curis And Autolus Rise On EHA Abstract Data
Potential Advances In AML and NHL
Promising early-stage data from two companies looking to break into crowded hemato-oncology markets.
You may also be interested in...
BMS Touts Breyanzi's Outpatient Administration As EU Approval Beckons
The US major won a positive opinion from the EU CHMP for Breyanzi with hopes the advantage of outpatient administration could help combat the lack of market impetus for CAR-T therapies.
Next-Gen CAR T & Novel SMA Drug Among New Entrants On EMA’s PRIME
Autolus, Scholar Rock, Rocket and Pfizer have managed to convince the European Medicines Agency that their investigational treatments merit a place on the regulator’s priory medicines scheme.
Vertex’s Sickle Cell Treatment Gets December Decision Date, On Track To Be First CRISPR Therapy
Vertex now looks likely to gain US approval for the first ever CRISPR gene edited therapy by the end of the year, but could face immediate competition from Bluebird Bio.